Skip to main content

Time to Clinical Response to Secukinumab Across Disease Domains Among Patients With Psoriatic Arthritis: a Pooled Post Hoc Analysis of 4 Phase 3 Trials

  • Sponsored by Novartis US Medical Affairs

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×